AI model aims to predict lung disease progression
NCT ID NCT07404423
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will collect data from 1000 people with idiopathic pulmonary fibrosis (IPF) across multiple Italian centers. Researchers will use machine learning to build a model that predicts disease progression, acute flare-ups, and response to treatment. The goal is to improve risk assessment for patients with this progressive lung disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a tool that helps doctors better predict how IPF will progress in individual patients, enabling more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. The machine-learning model may not be accurate enough for real-world use, and results may not apply outside the study population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults with idiopathic pulmonary fibrosis diagnosed according to international guidelines and local multidisciplinary team assessment, followed in routine care at participating Italian referral centres.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Diagnosis of idiopathic pulmonary fibrosis established according to international guidelines and local multidisciplinary team (MDT) assessment * Availability of baseline clinical and functional data * Availability of follow-up data for at least 12 months, or until a clinically relevant event (e.g., death, lung transplantation) Exclusion Criteria: * Interstitial lung disease other than IPF * Lung transplantation performed before the baseline (index) date * Absence of any follow-up information after baseline
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Patients and families build a living database of pulmonary fibrosis
- Can pulmonary fibrosis patients pull hard enough for their inhalers?
- Can a thousand patient records unlock better care for a rare lung disease?
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can we untangle the overlap of lung diseases? a new study aims to find out
- A blood test that could predict who survives a lung disease crisis?